Table 2.
Frequency of cardiovascular toxicities by treatment received
| Anthracycline only | VEGF inhibitor only | Anthracycline and VEGF inhibitor (N = 74) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| (N = 891) | (N = 200) | ||||||||
| N | (%) | N | (%) | aHR (95% CI) | N | (%) | aHR (95% CI) | p* | |
| Any Cardiovascular Toxicity | 230 | (25.8) | 38 | (19.0) | 0.72 (0.51–1.01) | 22 | (29.7) | 1.06 (0.70–1.61) | 0.15 |
| Hypertension | 172 | (21.0) | 30 | (17.4) | 0.84 (0.57–1.24) | 21 | (30.0) | 1.32 (0.85–2.05) | 0.27 |
| Cardiomyopathy/heart failure | 12 | (1.4) | 0 | (0) | - | 0 | (0) | - | * |
| Cardiomegaly | 3 | (0.3) | 1 | (0.5) | - | 0 | (0) | - | * |
| Pericardial disease | 21 | (2.4) | 2 | (1.0) | - | 0 | (0) | - | * |
| Myocardial infarction | 4 | (0.5) | 0 | (0) | - | 0 | (0) | - | * |
| Coronary artery disease | 1 | (0.1) | 0 | (0) | - | 0 | (0) | - | * |
| Conduction abnormality/dysrhythmia | 47 | (5.3) | 5 | (2.5) | 0.45 (0.18–1.13) | 2 | (2.7) | 0.48 (0.12–1.95) | 0.15 |
| Cerebrovascular event | 3 | (0.3) | 1 | (0.5) | - | 0 | (0) | - | * |
| Valvular degeneration | 5 | (0.6) | 1 | (0.5) | 0.72 (0.09–5.88) | 2 | (2.8) | 4.47 (0.82–24.43) | 0.17 |
| Peripheral vascular disease | 7 | (0.8) | 0 | (0) | - | 0 | (0) | - | * |
Groups were compared using Cox proportional hazard models adjusted for age and sex to evaluate time until onset of the cardiovascular toxicity. The anthracyline only group was used for the reference. Study participants with a baseline diagnosis of the cardiovasular toxicity were removed from the given analysis. E.g. the 30 patients in the VEGF group with hypertension are new onset hypertension after excluding the 28 patients with baseline hypertension
CI Confidence interval
*No statistical comparison was made due to infrequent events